Paradigm Biocapital Advisors LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Paradigm Biocapital Advisors LP reported 34 stock positions worth $2.8 billion. Its top holding was Nuvalent Class A (NUVL) at 11.0% of the portfolio, followed by Arcellx (ACLX, 9.3%) and Argenx SE - ADR (ARGX, 7.7%). Compared with Q4 2023, it opened 10 new positions, sold out of 5, added to 16 and reduced 5. The biggest buy was a new position in Sarepta Therapeutics (SRPT) and the biggest sale an exit from Mirati Therapeutics (MRTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001855655
- Portfolio Value
- $2.8B (Q1 2024)
- SEC Filing
- 0001855655-24-000005 ↗ filed May 15, 2024
Holdings Value
Holdings 34 stocks · $2.8B
| NUVL Nuvalent Inc. Class A | 11.04% | 4,177,830 | $313.7M | Add +8.3% |
| ACLX Arcellx Inc. | 9.35% | 3,818,095 | $265.5M | Add +4.4% |
| ARGX Argenx SE - ADR | 7.65% | 552,120 | $217.4M | Add +30.7% |
| IRON Disc Medicine Inc. | 5.24% | 2,389,902 | $148.8M | Add +0.2% |
| CRNX Crinetics Pharmaceuticals Inc. | 5.15% | 3,124,749 | $146.3M | Add +35.1% |
| SRPT Sarepta Therapeutics Inc. | 4.91% | 1,078,346 | $139.6M | New |
| IMCR Immunocore Holdings PLC-ADR | 4.09% | 1,787,176 | $116.2M | Add +22.9% |
| LEGN Legend Biotech Corp.-ADR | 3.91% | 1,982,006 | $111.2M | Add +4.6% |
| ARVN Arvinas Inc. | 3.80% | 2,614,935 | $107.9M | Add +180.8% |
| XENE Xenon Pharmaceuticals Inc. | 3.77% | 2,484,874 | $107.0M | Add +16.8% |
| TARS Tarsus Pharmaceuticals Inc. | 3.66% | 2,863,406 | $104.1M | Add +179.4% |
| CERE Cerevel Therapeutics Holding | 3.47% | 2,330,508 | $98.5M | No change |
| RVMD Revolution Medicines Inc. | 3.31% | 2,914,975 | $93.9M | New |
| OLMA Olema Pharmaceuticals Inc. | 3.15% | 7,903,600 | $89.5M | No change |
| VRDN Viridian Therapeutics Inc. | 3.10% | 5,031,420 | $88.1M | Add +4.9% |
| PCVX Vaxcyte Inc. | 2.98% | 1,239,995 | $84.7M | New |
| ALPN Alpine Immune Sciences Inc. | 2.96% | 2,121,163 | $84.1M | Reduce -33.2% |
| BCYC Bicycle Therapeutics PLC-ADR | 2.85% | 3,246,759 | $80.8M | Reduce -12.4% |
| ASND Ascendis Pharma A/S | 2.70% | 507,952 | $76.8M | Add +44.4% |
| KURA Kura Oncology Inc. | 2.35% | 3,135,387 | $66.9M | Add +148.3% |
| EWTX Edgewise Therapeutics Inc. | 1.57% | 2,446,373 | $44.6M | New |
| AUTL Autolus Therapeutics PLC | 1.44% | 6,425,803 | $41.0M | Reduce -49.0% |
| YMAB Y-Mabs Therapeutics Inc. | 1.28% | 2,233,610 | $36.3M | New |
| IMTX Immatics NV | 1.04% | 2,818,908 | $29.6M | Add +31.9% |
| IMVT Immunovant Inc. | 0.91% | 799,054 | $25.8M | New |
| CGEM Cullinan Therapeutics Inc. | 0.81% | 1,348,015 | $23.0M | New |
| APGE Apogee Therapeutics Inc. | 0.77% | 330,000 | $21.9M | New |
| CMPS Compass Pathways PLC | 0.70% | 2,390,988 | $19.9M | Add +5.5% |
| VOR Vor Biopharma Inc. | 0.54% | 6,457,293 | $15.3M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.52% | 944,917 | $14.9M | Add +136.2% |
| AGIO Agios Pharmaceuticals Inc. | 0.41% | 400,000 | $11.7M | New |
| CRBU Caribou Biosciences Inc. | 0.39% | 2,172,620 | $11.2M | Reduce -25.7% |
| CRGX Cargo Therapeutics Inc. | 0.12% | 147,959 | $3.3M | Reduce -55.6% |
| KYTX Kyverna Therapeutics Inc. | 0.04% | 50,000 | $1.2M | New |
Portfolio Sells Q4 2023 → Q1 2024
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −4.25 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −2.90 |
| AUTL Autolus Therapeutics PLC | Reduce -49.0% | 1.44% | −2.36 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −1.74 |
| ZLAB Zai Lab Ltd.-ADR | Sold out | 0.00% | −1.40 |
| CRBU Caribou Biosciences Inc. | Reduce -25.7% | 0.39% | −0.39 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -12.4% | 2.85% | −0.30 |
| CRGX Cargo Therapeutics Inc. | Reduce -55.6% | 0.12% | −0.25 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.15 |
| ALPN Alpine Immune Sciences Inc. | Reduce -33.2% | 2.96% | +0.12 |
Portfolio Buys Q4 2023 → Q1 2024
| SRPT Sarepta Therapeutics Inc. | New | 4.91% | +4.91 |
| RVMD Revolution Medicines Inc. | New | 3.31% | +3.31 |
| PCVX Vaxcyte Inc. | New | 2.98% | +2.98 |
| TARS Tarsus Pharmaceuticals Inc. | Add +179.4% | 3.66% | +2.69 |
| ARVN Arvinas Inc. | Add +180.8% | 3.80% | +2.00 |
| EWTX Edgewise Therapeutics Inc. | New | 1.57% | +1.57 |
| KURA Kura Oncology Inc. | Add +148.3% | 2.35% | +1.50 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +35.1% | 5.15% | +1.29 |
| YMAB Y-Mabs Therapeutics Inc. | New | 1.28% | +1.28 |
| IMVT Immunovant Inc. | New | 0.91% | +0.91 |
| CGEM Cullinan Therapeutics Inc. | New | 0.81% | +0.81 |
| APGE Apogee Therapeutics Inc. | New | 0.77% | +0.77 |
| ASND Ascendis Pharma A/S | Add +44.4% | 2.70% | +0.63 |
| AGIO Agios Pharmaceuticals Inc. | New | 0.41% | +0.41 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +136.2% | 0.52% | +0.24 |
| ARGX Argenx SE - ADR | Add +30.7% | 7.65% | +0.12 |
| KYTX Kyverna Therapeutics Inc. | New | 0.04% | +0.04 |
| IMTX Immatics NV | Add +31.9% | 1.04% | −0.01 |
| ACLX Arcellx Inc. | Add +4.4% | 9.35% | −0.17 |
| CMPS Compass Pathways PLC | Add +5.5% | 0.70% | −0.23 |
| IMCR Immunocore Holdings PLC-ADR | Add +22.9% | 4.09% | −0.57 |
| XENE Xenon Pharmaceuticals Inc. | Add +16.8% | 3.77% | −0.83 |
| IRON Disc Medicine Inc. | Add +0.2% | 5.24% | −1.22 |
| LEGN Legend Biotech Corp.-ADR | Add +4.6% | 3.91% | −1.43 |
| VRDN Viridian Therapeutics Inc. | Add +4.9% | 3.10% | −1.79 |
| NUVL Nuvalent Inc. Class A | Add +8.3% | 11.04% | −2.26 |
Options Activity Q4 2023 → Q1 2024
| AMAM New Ambrx Biopharma Inc. | call | Sold out | 150,000 | $2.1Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 28 | $5.3B | RVMD, NUVL, EWTX, GMAB, SYRE |
| Q1 2026 | 35 | $4.9B | ACLX, RVMD, NUVL, PCVX, EWTX |
| Q4 2025 | 29 | $3.7B | NUVL, RVMD, ACLX, GMAB, TARS |
| Q3 2025 | 33 | $3.4B | NUVL, MRUS, ACLX, RVMD, TARS |
| Q2 2025 | 28 | $2.3B | NUVL, ACLX, MRUS, RVMD, TARS |
| Q1 2025 | 27 | $2.2B | NUVL, ACLX, RVMD, ONC, MRUS |
| Q4 2024 | 28 | $2.9B | NUVL, ACLX, ARGX, RVMD, JANX |
| Q3 2024 | 31 | $2.9B | NUVL, ACLX, ARGX, RVMD, CRNX |
| Q2 2024 | 35 | $2.6B | NUVL, ARGX, ACLX, RVMD, SRPT |
| Q1 2024 | 34 | $2.8B | NUVL, ACLX, ARGX, IRON, CRNX |